FDA approve first biologic drug for use in patients with non-radiographic Axial Spondyloarthritis

NEWSFLASH!

On March 28, 2019 the U.S. Food and Drug Administration approved certolizumab pegol (Cimzia®) for use in patients with non-radiographic Axial Spondyloarthritis. It is the first time that a biologic drug has been approved for nrAxSpA.

Read the full FDA press release

Other NEWS

Rheumafit

Online exercise videos for AxSpA/AS and other arthritis patients

ASIF Newsletter September 2019

This newsletter includes articles about our recent name change to Axial Spondyloarthritis

Read More